ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Executive Director, Global CMC Lead at Revolution Medicines - ApplyBlast

Executive Director, Global CMC Lead

Revolution Medicines

6 months ago

3.5 on Glassdoor

Redwood City, California

Onsite

Full Time

Executive

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

An Executive Director, Global CMC Lead at Revolution Medicines oversees the global CMC strategy for late-stage clinical oncology programs, ensuring regulatory compliance, supply continuity, and strategic alignment with development and commercialization goals.

Skills

Qualifications

PhD (strongly preferred), MS, or equivalent in Chemistry, Chemical Engineering, Pharmaceutical Sciences, or related discipline15+ years of progressive CMC experience in the pharmaceutical or biotechnology industry, with a strong focus on small moleculesDemonstrated leadership of CMC activities from early development through commercialization life cycleProven experience leading global regulatory submissions and interacting with major health authorities (FDA, EMA, PMDA)Deep expertise in small molecule API and drug product development, manufacturing, and control strategies

About Revolution Medicines

revmed.com

Headquarters

Redwood City, California, United States

Company Size

201-500 employees

Founded

2014

View Profile

Revolution Medicines (RevMed) is a biopharmaceutical company dedicated to discovering, developing, and delivering novel targeted medicines for patients with cancer. Their mission focuses specifically on "revolutionizing treatment for patients with RAS‑addicted cancers" through precision-targeted therapies. The company emphasizes a science-driven, end-to-end approach from discovery to delivery. RevMed brands its team as "Revolutionaries" committed to transforming outcomes for people with RAS‑driven tumors.